BACKGROUND: Upregulation of the cell cycle associated genes, p16/CDKN2 and the retinoblastoma susceptibility gene (Rb), is commonly seen during the proliferation of normal cells. An inverse relation between the expression of p16/CDKN2 and Rb has been noted in many tumours, but has not yet been determined in oesophageal squamous carcinoma. AIMS: To investigate p16/CDKN2 genetic alterations and both the p16/CDKN2 and the Rb protein (pRb) immunophenotypes in oesophageal squamous carcinoma. METHODS: Twenty primary oesophageal squamous carcinomas were examined for mutations in p16/CDKN2 by the polymerase chain reaction, single stranded conformational polymorphism, and DNA sequencing. Synthesis of p16/CDKN2 and pRb proteins was determined by immunohistochemistry in 19 specimens of formalin fixed, paraffin wax embedded tissues. RESULTS: Mutations of p16/CDKN2 were not detected in exons 1 and 2. In only one case, G to C and C to T base changes were detected in a non-coding region of exon 3. Expression of p16/CDKN2 and Rb was observed in both normal and neoplastic areas of tissue sections, indicating neither consistent homozygous deletion nor consistent hypermethylation of the genes in tumours. Fourteen tumours showed an inverse expression of p16/CDKN2 and Rb. An increased percentage of cells that immunostained positively for p16/CDKN2 but not for pRb was observed in eight tumours, five of which had no detectable pRb, suggesting defective Rb expression in these oesophageal squamous carcinomas. CONCLUSIONS: These results indicate that p16/CDKN2 mutations occur infrequently in oesophageal squamous carcinoma. The alteration of the Rb gene is suggested as an important step in the development of these tumours.
BACKGROUND: Upregulation of the cell cycle associated genes, p16/CDKN2 and the retinoblastoma susceptibility gene (Rb), is commonly seen during the proliferation of normal cells. An inverse relation between the expression of p16/CDKN2 and Rb has been noted in many tumours, but has not yet been determined in oesophageal squamous carcinoma. AIMS: To investigate p16/CDKN2 genetic alterations and both the p16/CDKN2 and the Rb protein (pRb) immunophenotypes in oesophageal squamous carcinoma. METHODS: Twenty primary oesophageal squamous carcinomas were examined for mutations in p16/CDKN2 by the polymerase chain reaction, single stranded conformational polymorphism, and DNA sequencing. Synthesis of p16/CDKN2 and pRb proteins was determined by immunohistochemistry in 19 specimens of formalin fixed, paraffin wax embedded tissues. RESULTS: Mutations of p16/CDKN2 were not detected in exons 1 and 2. In only one case, G to C and C to T base changes were detected in a non-coding region of exon 3. Expression of p16/CDKN2 and Rb was observed in both normal and neoplastic areas of tissue sections, indicating neither consistent homozygous deletion nor consistent hypermethylation of the genes in tumours. Fourteen tumours showed an inverse expression of p16/CDKN2 and Rb. An increased percentage of cells that immunostained positively for p16/CDKN2 but not for pRb was observed in eight tumours, five of which had no detectable pRb, suggesting defective Rb expression in these oesophageal squamous carcinomas. CONCLUSIONS: These results indicate that p16/CDKN2 mutations occur infrequently in oesophageal squamous carcinoma. The alteration of the Rb gene is suggested as an important step in the development of these tumours.
Authors: C H Spruck; M Gonzalez-Zulueta; A Shibata; A R Simoneau; M F Lin; F Gonzales; Y C Tsai; P A Jones Journal: Nature Date: 1994-07-21 Impact factor: 49.962
Authors: X Zhou; H Suzuki; Y Shimada; M Imamura; J Yin; H Y Jiang; L Tarmin; J M Abraham; S J Meltzer Journal: Genes Chromosomes Cancer Date: 1995-08 Impact factor: 5.006
Authors: M Gonzalez-Zulueta; C M Bender; A S Yang; T Nguyen; R W Beart; J M Van Tornout; P A Jones Journal: Cancer Res Date: 1995-10-15 Impact factor: 12.701
Authors: A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach Journal: Proc Natl Acad Sci U S A Date: 1994-11-08 Impact factor: 11.205
Authors: H Igaki; H Sasaki; Y Tachimori; H Kato; H Watanabe; T Kimura; Y Harada; T Sugimura; M Terada Journal: Cancer Res Date: 1995-08-01 Impact factor: 12.701
Authors: Simone S Contu; Paulo C Contu; Daniel C Damin; Renato B Fagundes; Fabiano Bevilacqua; Aline S Rosa; João C Prolla; Luis F Moreira Journal: World J Gastroenterol Date: 2007-03-21 Impact factor: 5.742
Authors: Eva Cristobal; Begona Arribas; Juan Tardio; Jose A. AIcazar; Juan C. Matinez-Montero; Rafael Carrion; Jose R. Polo; Laura Gil; Marta Azanedo; Jose M. Rojas; Javier Menarguez Journal: Endocr Pathol Date: 2000 Impact factor: 3.943
Authors: Behnoush Abedi-Ardekani; Nazir Ahmad Dar; Mohammad Muzaffar Mir; Showkat Ahmad Zargar; M Muqbool Lone; Ghyslaine Martel-Planche; Stéphanie Villar; Mounia Mounawar; Farrokh Saidi; Reza Malekzadeh; Pierre Hainaut Journal: BMC Cancer Date: 2012-12-17 Impact factor: 4.430